glp-1 substance use disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) and disorders: An emerging pharmacotherapeutic target Glucagon-like peptide-1 receptor agonists and

L., Pipingas, A., Macpherson, H., Wesnes, K., Ou, R., Hare, D., de Haan, J., Head, G., Lansjoen, P., Langsjoen, A., Tan, B., Pase, M

Making sense of dynamic market shifts MedTech companies are already considering how best to articulate the continued value of their products to audiences including regulators, physicians, payers, and analysts

95% CI: 1.181.97)

All volunteers had to abstain from other medications, supplementary vitamins, and alcohol intake for 2 weeks prior to enrollment and throughout the study

Despite the availability of conventional diabetes treatments, kidney complications persist, largely due to the complex interplay between high blood sugar, vascular stress, and inflammation